LISATA THERAPEUTICS INC. - COMMON STOCK

Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

06 سبتمبر 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

05 سبتمبر 2023 05:00:01 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

14 أغسطس 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

08 أغسطس 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

07 أغسطس 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

11 يوليو 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference

12 يونيو 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1

24 مايو 2023 05:00:01 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

09 مايو 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time

02 مايو 2023 06:07:03 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in May

27 أبريل 2023 06:00:01 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

20 أبريل 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

18 أبريل 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

30 مارس 2023 13:05:01 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time

23 مارس 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in February

01 فبراير 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

10 نوفمبر 2022 13:05:01 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022

07 نوفمبر 2022 05:00:02 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time

03 نوفمبر 2022 05:00:03 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in October 2022

06 أكتوبر 2022 05:30:00 بحسب Nasdaq GlobeNewswire